Gefapixant Tablets (Lifnua) is a selective P2X3 receptor antagonist specifically indicated for symptomatic treatment in patients with refractory chronic cough.

Dosage and Administration of Gefapixant Tablets (Lifnua)

Standard Adult Dosage

The conventional adult dosage of Gefapixant Tablets is 45 mg orally twice daily.

This dosage is determined based on results from multiple Phase III clinical trials, which demonstrated effective reduction in cough frequency in patients with chronic cough and manageable safety profile.

Administration Precautions

This product is for symptomatic treatment, not etiological treatment of cough.

Its use should only be considered after comprehensive evaluation and exclusion of other treatable causes of cough. Long-term blind use is not recommended; efficacy and safety should be regularly assessed.

Dosage Adjustments for Gefapixant Tablets (Lifnua)

Dosage Adjustments in Renal Impairment

Gefapixant Tablets are primarily excreted via the kidneys, and renal function status significantly affects the drug's exposure level in the body.

Mild to moderate renal impairment (eGFR ≥ 30 mL/min/1.73m²): No dosage adjustment is required; continue with 45 mg twice daily.

Severe renal impairment (eGFR < 30 mL/min/1.73m²) without dialysis: The recommended dosage is adjusted to 45 mg once daily to reduce the risk of drug accumulation.

End-stage renal disease (ESRD) requiring dialysis: No recommended dosage is available currently. Use with caution and close monitoring.

Patients with Hepatic Impairment

Since Gefapixant Tablets are mainly excreted via the kidneys, hepatic impairment has minimal impact on its pharmacokinetics, and dosage adjustment is generally not required.

Use in Special Populations for Gefapixant Tablets (Lifnua)

Pregnant Women

Animal studies have shown that gefapixant can cross the placenta and cause a slight decrease in fetal weight at high doses.

Use in pregnant women is only permitted if the potential therapeutic benefit outweighs the potential risk to the fetus.

Lactating Women

Gefapixant is excreted in breast milk. The decision to continue breastfeeding or discontinue the drug should be made after comprehensive evaluation of the necessity of drug treatment and the benefits of breastfeeding.

Children and Adolescents

Clinical trials in patients under 18 years of age have not been conducted, and efficacy has not been established. Use is not recommended.

Patients with a History of Allergies

Contraindicated in patients with hypersensitivity to any component of this product.

Gefapixant contains a sulfonamide group in its structure; patients allergic to sulfonamide drugs may be at risk of cross-allergy. Use with caution.